Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01245049
Other study ID # 111763
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 1, 2011
Est. completion date April 2, 2012

Study information

Verified date June 2018
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and 4-year-old children.


Recruitment information / eligibility

Status Completed
Enrollment 387
Est. completion date April 2, 2012
Est. primary completion date March 27, 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 4 Years
Eligibility Inclusion Criteria:

- Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol should be enrolled in the study.

- A male or female child of 3 or 4 years of age at the time of booster vaccination (up to, but excluding 5 years of age).

- Subjects who have received a complete three-dose primary vaccination with diphtheria-tetanus-acellular pertussis (DTPa) vaccine and inactivated poliovirus (IPV) vaccine in the first six months of life, in line with recommendations in the United Kingdom (UK).

- Subjects who received a first dose of a live attenuated measles-mumps-rubella vaccine within the second year of life, in line with recommendations in the UK.

- Written informed consent obtained from the parent(s)/LAR(s) of the subject at the time of enrolment.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

- Child in care.

- Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.

- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.

- Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with the exception of inactivated influenza vaccine.

- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

- Previous booster vaccination against diphtheria, tetanus, pertussis, poliomyelitis since primary vaccination in the first year of life.

- Previous measles, mumps and/or rubella second dose vaccination.

- Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps and/or rubella disease.

- Known exposure to measles, mumps and/or rubella within 30 days prior to study start.

- Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.

- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.

- Administration of immunoglobulin and/or any blood products within the three months preceding the booster dose or planned administration during the study period.

- Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation.

- Occurrence of any of the following adverse events after a previous administration of a DTP vaccine:

- Hypersensitivity reaction to any component of the vaccine;

- Encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine;

- Fever >= 40°C within 48 hours of vaccination, not due to another identifiable cause;

- Collapse or shock-like state within 48 hours of vaccination;

- Convulsions with or without fever, occurring within 3 days of vaccination.

- Acute disease and/or fever at the time of enrolment or within 24 hours of study vaccine administration.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Boostrix PolioTM
Single dose, intramuscular administration.
RepevaxTM
Single dose, intramuscular administration.
PriorixTM
Single dose, intramuscular or subcutaneous administration.

Locations

Country Name City State
United Kingdom GSK Investigational Site Atherstone Warwickshire
United Kingdom GSK Investigational Site Axbridge Somerset
United Kingdom GSK Investigational Site Bangor
United Kingdom GSK Investigational Site Bolton, Nr Manchester
United Kingdom GSK Investigational Site Bristol
United Kingdom GSK Investigational Site Crumpsall, Manchester
United Kingdom GSK Investigational Site Exeter
United Kingdom GSK Investigational Site Lancashire
United Kingdom GSK Investigational Site Oxford
United Kingdom GSK Investigational Site Randalstown
United Kingdom GSK Investigational Site Southampton Hampshire
United Kingdom GSK Investigational Site St Austell Cornwall
United Kingdom GSK Investigational Site Taunton Somerset

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With a Booster Response to Diphtheria (D) and Tetanus (T) Antigens Booster response was defined as: For initially seronegative subjects [i.e. pre-vaccination concentration below (<) cut-off value of 0.1 international units per milliliter (IU/mL)] antibody concentrations at least four times the assay cut-off [post vaccination concentration greater than or equal to (=) 0.4 IU/ml]. For initially seropositive subjects (pre-vaccination concentration = 0.1 IU/ml), an increase in antibody concentrations of at least four times the Pre booster vaccination concentration. At Month 1, one month after the booster vaccination
Primary Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). At Month 1, one month after the booster vaccination
Primary Anti-Polio Virus Type 1, 2 and 3 Antibody Titers Antibody titers were presented as geometric mean titers (GMTs). At Month 1, one month after the booster vaccination
Secondary Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) A seroprotected subject was defined a subject with anti-D and anti-T antibody concentrations = 0.1 international units per millilitre (IU/mL). Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN A seropositive subject for anti-PT, anti-FHA and anti-PRN was a subject whose antibody concentration was = 5 EL.U/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 A seroprotected subject was defined as a subject with anti-polio type 1, 2 and 3 antibody titres = the value of 8. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Seropositive Subjects for Anti-measles Antibody A seropositive subject was defined as a subject with anti-measles antibody titers = 150 mIU/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Seropositive Subjects for Anti-mumps Antibody A seropositive subject was defined as a subject with anti-mumps antibody titers = 231 U/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Seropositive Subjects for Anti-rubella Antibody A seropositive subject was defined as a subject with anti-rubella antibody titers = 4 IU/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Anti-D and Anti-T Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. At Month 0, before the booster vaccination
Secondary Anti-mumps Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in U/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Anti-measles Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Anti-rubella Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Anti-Polio Type 1, 2 and 3 Antibody Titers Antibody titers were presented as geometric mean titers (GMTs). At Month 0, before the booster vaccination
Secondary Number of Subjects With a Booster Response to PT, FHA and PRN Antigens Booster response was defined as: For initially seronegative subjects (pre-vaccination concentration < 5 EL.U/mL), antibody concentrations at least four times the assay cut-off (post vaccination concentration = 20 EL.U/mL). For initially seropositive subjects (with pre-vaccination concentration = 5 EL.U/mL and < 20 EL.U/mL), an increase in antibody concentrations of at least four times the Pre booster vaccination concentration. For initially seropositive subjects (with pre-vaccination concentration = 20 EL.U/mL), an increase in antibody concentrations of at least two times the Pre booster vaccination concentration. At Month 1, one month after the booster vaccination
Secondary Number of Subjects With Booster Response for Polio Type 1, 2 and 3 Antigens Booster response defined as: For initially seronegative subjects, antibody titers at least four times the cut-off (post-vaccination titer = 32); For initially seropositive subjects, an increase in antibody titers of at least four times the Pre booster vaccination titer. At Month 1, one month after the booster vaccination
Secondary Number of Seroconverted Subjects for Anti-measles Seroconversion for anti-measles was defined as the appearance of antibodies after vaccination in subjects who were initially seronegative [with antibody concentrations = 150 milli-international units per millilitre (mIU/mL)]. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Seroconverted Subjects for Anti-mumps Seroconversion for anti-mumps was defined as the appearance of antibodies after vaccination in subjects who were initially seronegative [with antibody concentrations = 231 units per millilitre (U/mL)]. Before (Month 0) and one month after (Month 1) the booster vaccination
Secondary Number of Subjects With Any Solicited Local Symptoms Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. During the 4-day (Days 0-3) follow-up period after booster vaccination
Secondary Number of Subjects With Any Solicited General Symptoms Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. During the 4-day (Days 0-3) follow-up period after booster vaccination
Secondary Number of Subjects With Any Unsolicited Adverse Events (AEs) An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. During the 31-day (Days 0-30) follow-up period after booster vaccination
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. During the entire study period (From Day 0 to Month 1)
See also
  Status Clinical Trial Phase
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population Phase 3
Completed NCT00385255 - Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Phase 3